ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On
The Offering is being made pursuant to a prospectus supplement dated
The Underwriting Agreement contains customary representations, warranties, and agreements by the Company, and customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties, and termination provisions.
A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this Current
Report on Form 8-K and is incorporated herein by reference. A copy of the
opinion of
In connection with the Offering, certain information relating to Part II, Item 14 of the above referenced registration statement under the heading "Other Expenses of Issuance and Distribution" is being filed as Exhibit 99.1 to this Current Report on Form 8-K to be incorporated by reference into such registration statement.
The foregoing description of the Offering by the Company and the documentation related thereto does not purport to be complete and is qualified in its entirety by reference to such Exhibits.
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(e) In connection with the Offering, on
ITEM 7.01 REGULATION FD DISCLOSURE
On
The press release and the information in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits Exhibit No. Exhibit 1.1 Underwriting Agreement datedJanuary 22, 2020 by and amongImmunoGen, Inc. andJefferies LLC, Cowen and Company, LLC andWilliam Blair & Company, L.L.C. , as representatives of the several underwriters named in Schedule 1 thereto. 5.1 Opinion ofMintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C . Consent ofMintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C . 23.1 (included in the opinion filed as Exhibit 5.1). Information relating to Item 14 of the Registration Statement on 99.1 Form S-3 (File No. 333-223507). 99.2 Press release ofImmunoGen, Inc. datedJanuary 22, 2020 . Cover Page Interactive Data File (embedded within the Inline XBRL 104 (eXtensible Business Reporting Language) document).
© Edgar Online, source